Previous 10 | Next 10 |
AVEO Oncology (AVEO) has concluded a previously announced stock offering of 6.9M shares, including 900K shares purchased by underwriters.The company has earned gross proceeds of $55.2M.The proceeds will be used for working capital and general corporate purposes, including commercialization of...
AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes the full exercise by the underwriters of their option to purchase an additional 900,000 shares, at a price to the pub...
AVEO Oncology (AVEO) has priced its public offering of 6M common shares at $8.00/share, for expected gross proceeds of $48M.Underwriters' over-allotment is an additional 900K shares. Net proceeds will be used for working capital and general corporate purposes, including commercialization of F...
AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $8.00 per share. The gross proceeds to AVEO from the offering are expected to be $48.0 million before...
Frequency Therapeutics (FREQ) -71% after releases new data. from two FX-322 clinical studies; plans to advance single-dose regimen.Anixa Biosciences (ANIX) -23% after raises previously announced bought deal offering of common stock to $22.5M.Windtree Therapeutics (WIN...
AVEO Oncology (AVEO) trades 5.8% down after hours on commencing an underwritten public offering of 5M shares; underwriters granted 30-day option to purchase up to an additional 750K shares.Offer size, terms have not yet been disclosed.Net proceeds to be used for general corpora...
AVEO Oncology (AVEO) announces that its renal cell carcinoma treatment FOTIVDA (tivozanib) is now commercially available in the United States.FOTIVDA is available through a limited distribution network comprised of specialty pharmacies (Biologics & Onco360) and special...
- FOTIVDA is the First Therapy Approved for Adults with Relapsed or Refractory Advanced RCC Following Two or More Prior Systemic Therapies – - AVEO ACE Patient Support Program in Place to Assist with Access, Affordability, and Treatment Adherence - AVEO Oncolo...
Tivo was recently approved by the FDA for 3rd line RCC. The company has a decent pipeline. However, they're low on cash, and they need to make some money off of the approved drug. For further details see: AVEO: Drug Approved, But Still A Long Way To Go Before Self Suffic...
AVEO Pharmaceuticals (AVEO): Q4 GAAP EPS of -$0.44 misses by $0.06.Revenue of $0.89M (+17.1% Y/Y) misses by $2.11M.Ended 2020 with $61.8 million in cash, cash equivalents, and marketable securities as compared with $47.7 million at December 31, 2019.Guidance: AVEO believes that its $61.8...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...